Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Smoothened”

23 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 23 results

Testing effectiveness (Phase 2)Ended earlyNCT01357655
What this trial is testing

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Who this might be right for
Leukemia
Bristol-Myers Squibb 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT06357988
What this trial is testing

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphatic System Neoplasm+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Ended earlyNCT02254551
What this trial is testing

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
SCRI Development Innovations, LLC 7
Testing effectiveness (Phase 2)Study completedNCT01842646
What this trial is testing

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)
H. Lee Moffitt Cancer Center and Research Institute 35
Not applicableStudy completedNCT01529450
What this trial is testing

Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors

Who this might be right for
Basal Cell Carcinoma
Anne Chang 11
Early research (Phase 1)Study completedNCT01576666
What this trial is testing

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Who this might be right for
Dose EscalationSafetyPreliminary Efficacy+9 more
Novartis Pharmaceuticals 120
Testing effectiveness (Phase 2)Study completedNCT05199584
What this trial is testing

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Who this might be right for
Solid Tumors With PTCH1 Loss-of-function Mutations
Endeavor Biomedicines, Inc. 20
Early research (Phase 1)Study completedNCT01208831
What this trial is testing

An East Asian Study of LDE225

Who this might be right for
Advanced Solid Tumor CancersMedulloblastomaBasal Cell Carcinoma
Novartis Pharmaceuticals 45
Early research (Phase 1)Study completedNCT01456676
What this trial is testing

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

Who this might be right for
Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Novartis Pharmaceuticals 11
Early research (Phase 1)Study completedNCT05817240
What this trial is testing

A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

Who this might be right for
Idiopathic Pulmonary Fibrosis
Endeavor Biomedicines, Inc. 21
Testing effectiveness (Phase 2)Study completedNCT01218477
What this trial is testing

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

Who this might be right for
Leukemia
Bristol-Myers Squibb 33
Testing effectiveness (Phase 2)Ended earlyNCT02226172
What this trial is testing

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Who this might be right for
Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Pfizer 21
Early research (Phase 1)Study completedNCT02323139
What this trial is testing

LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients

Who this might be right for
MDS
Groupe Francophone des Myelodysplasies 23
Large-scale testing (Phase 3)WithdrawnNCT03070691
What this trial is testing

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Who this might be right for
Basal Cell Carcinoma
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT01787552
What this trial is testing

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Who this might be right for
Primary MyelofibrosisThrombocytosisEssential Thrombocythemia+7 more
Novartis Pharmaceuticals 50
Early research (Phase 1)Study completedNCT00670189
What this trial is testing

BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Who this might be right for
Hedgehog PathwaySmoothenedBasal Cell Carcinoma (BCC)+1 more
Bristol-Myers Squibb 53
Testing effectiveness (Phase 2)Study completedNCT03390296
What this trial is testing

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center 50
Early research (Phase 1)Study completedNCT01106508
What this trial is testing

A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsRecurrent or Refractory MedulloblastomaLocally Advanced or Metastatic Basal Cell Carcinoma
Novartis Pharmaceuticals 57
Testing effectiveness (Phase 2)Study completedNCT00961896
What this trial is testing

A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients

Who this might be right for
Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients
Novartis Pharmaceuticals 18
Early research (Phase 1)Study completedNCT00880308
What this trial is testing

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor CancersMedulloblastomaBasal Cell Carcinoma
Novartis Pharmaceuticals 103
Load More Results